FDA Approves Zevaskyn: First Gene Therapy for Recessive Dystrophic Epidermolysis Bullosa

The Food and Drug Administration (FDA) has approved Zevaskyn, a gene therapy for recessive dystrophic epidermolysis bullosa (RDEB). The FDA approval marks Zevaskyn as the first gene therapy available for this condition. Zevaskyn is designed to promote wound healing and relieve pain in patients with RDEB. RDEB is a rare genetic disorder characterized by fragile skin that blisters and tears easily. The gene therapy aims to address the underlying genetic defect that causes the disease. The treatment offers a new therapeutic option for individuals affected by this debilitating condition.

Newsflash | Powered by GeneOnline AI
Date: April 29, 2025

Related posts:

PI3K and AKT Inhibitors Linked to Hyperglycemia in HR+ Breast Cancer Patients STAT’s Weekly Health Tech Newsletter Delivers Tech and Life Sciences Insights Every Tuesday 4DMT’s 4D-150 Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Federal Order Mandates FDA and EPA to Expedite Approval of Domestic Manufacturing Plants

Author

Mark Chiang